Neu2000 is primarily investigated for its neuroprotective properties, particularly in the context of stroke and other neurological conditions. It functions as a dual-acting agent, targeting both NMDA receptor-mediated excitotoxicity and oxidative stress, which are key contributors to neuronal damage. In preclinical studies, Neu2000 has shown promise in reducing brain injury and improving outcomes following ischemic stroke. Its ability to modulate glutamate toxicity while simultaneously scavenging free radicals makes it a potential therapeutic candidate for acute brain injuries. Additionally, research suggests it may have applications in treating neurodegenerative diseases like Alzheimer's and Parkinson's, where excitotoxicity and oxidative stress play significant roles. Clinical trials are ongoing to further evaluate its efficacy and safety in humans.